Engage Bio develops non-viral DNA medicines for genetic and therapeutic applications. The company creates the Tethosome platform, which combines therapeutic DNA, messenger RNA, and lipid nanoparticle delivery technology to support durable and repeatable gene expression while reducing immune system activation. Its platform is designed to improve DNA localization within cells and increase therapeutic protein production for applications such as gene replacement, oncology, and long-term protein expression. Engage Bio also works with research and development partners to apply its technology across multiple therapeutic programs and genetic medicine initiatives.